Kintara Therapeutics, Inc.
KTRA
NASDAQ
| 06/30/2024 | 03/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 52.98% | 64.43% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.39% | 104.61% | |||
| Operating Income | -14.39% | -104.61% | |||
| Income Before Tax | -15.56% | -96.58% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -15.56% | -96.58% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -15.56% | -96.58% | |||
| EBIT | -14.39% | -104.61% | |||
| EBITDA | -14.01% | -106.87% | |||
| EPS Basic | 6.54% | 80.89% | |||
| Normalized Basic EPS | 6.52% | 80.87% | |||
| EPS Diluted | 6.54% | 80.89% | |||
| Normalized Diluted EPS | 6.52% | 80.87% | |||
| Average Basic Shares Outstanding | 23.63% | 927.60% | |||
| Average Diluted Shares Outstanding | 23.63% | 927.60% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | 1.00% | 0.49% | |||
